| Project/Area Number |
25293008
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Partial Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Physical pharmacy
|
|---|
| Research Institution | Gifu Pharmaceutical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
Hara Hideaki 岐阜薬科大学, 薬学部, 教授 (20381717)
Tahara Kohei 岐阜薬科大学, 薬学部, 講師 (30454325)
Onodera Risako 岐阜薬科大学, 薬学部, 助教 (60720399)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥19,370,000 (Direct Cost: ¥14,900,000、Indirect Cost: ¥4,470,000)
Fiscal Year 2015: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2014: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2013: ¥11,700,000 (Direct Cost: ¥9,000,000、Indirect Cost: ¥2,700,000)
|
|---|
| Keywords | リポソーム / 核酸医薬 / 点眼 / 網膜 / 肺疾患 / 前臨床試験 / ボナック核酸 / 経肺 / DDS |
|---|
| Outline of Final Research Achievements |
For the purpose of design of the topical formulations of BONAC nucleic, the optimal liposomal formulation with the fluorescent substance, selected as its model, was established. By using these liposomal systems, their behavior was analyzed after pulmonary or ophthalmic administration. With the same technique, it was confirmed that surface property control with suitable polymers lead to controlling the behavior of carriers after administration. At the same time, the BONAC nucleic acid encapsulating liposomes were prepared to take essential data for connecting to the pre-clinical studies aimed at practical use, including stability data. From all these results, we have demonstrated possibilities for BONAC nucleic to be used as an effective drug both in the treatment of the posterior segment related disease in the eye with eye drops and treatment of special lung disease with the prolonged residence type liposomal formulation.
|
